- Bepirovirsen (antisense oligonucleotide) for chronic hepatitis B is under Priority Review in China (accepted April 2026) after positive B-Well 1/2 phase III results showing significant functional cure rates.
- GSK granted CTTQ (Sino Biopharmaceutical) exclusive China launch rights; CTTQ will handle importation, distribution, hospital access and promotion across 5,000+ medical centres.
- CTTQ will purchase bepirovirsen from GSK under an initial 5.5-year supply agreement; GSK remains marketing authorisation holder and retains regulatory, quality and pharmacovigilance responsibilities.
- GSK can review certain early-stage SBP Group pipeline assets to evaluate potential collaborations outside China.
Deal overview
GSK entered an exclusive collaboration with Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) to accelerate the launch of bepirovirsen in mainland China, with CTTQ handling importation, distribution, hospital access and promotional activities.
Regulatory & clinical status
Bepirovirsen, an investigational antisense oligonucleotide, received Breakthrough Therapy designation in China in August 2021 and was accepted for Priority Review in April 2026; Phase III B‑Well 1 and 2 trials showed statistically significant, clinically meaningful functional cure rates.
Commercial terms
CTTQ will purchase bepirovirsen from GSK under agreed supply terms for an initial 5.5‑year term; GSK remains the marketing authorisation holder and retains regulatory, quality, pharmacovigilance and global medical responsibilities.
Disease context
Chronic hepatitis B affects an estimated 75 million people in China and is a national health priority; the 2025–2030 National Action Plan targets functional cure to reduce long‑term complications, including liver cancer.
Future options
The agreement gives GSK the right to review certain early‑stage SBP Group pipeline assets to evaluate potential collaboration opportunities outside China.
